Insulin-Mediated and Non-Insulin-Mediated Metabolic Effects of Gastroenteropancreatic Peptides in Type I and Type II Diabetes

  • J. Dupre
  • A. Baer
  • M. Lee
  • T. J. McDonald
  • J. Radziuk
  • N. W. Rodger
  • S. Sullivan
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 189)


The recognition of secretion as a physiological regulator of the exocrine secretions of the pancreas in 1902 led to generalization of the concept of hormonal control of digestive sections,1 and excited interest in such mechanisms as possible mediators of the functions of the pancreas in control of glycemia.2 According to the “incretin” hypothesis, hormones released from the gastrointestinal tract in response to ingestion of nutrients serve to activate the glucoregulatory function of the pancreas.3 With the later identification of insulin as a hormonal effector of these functions, the hypothesis was adapted by suggesting that incretin stimulates insulin secretion. A variety of experiments with crude extracts of gastrointestinal tissues yielded conflicting results4, and following the recognition of direct effects of glucose on the release of insulin interest in incretin waned. However in the early 1960’s it was recognized that the glycemic stimulus to insulin secretion cannot account for differences in blood insulin levels after enteral and parenteral administration of glucose, which are also accompanied by apparent differences in glucose disposa1.5,6 These observations revived the hormonal hypothesis for stimulation of the beta cells by gastrointestinal factors, and a renewed search for candidate peptides that might fill this role was undertaken. Studies of these phenomena have yielded evidence related to the pathophysiology of disorders of intermediary metabolism in diabetes, with indications of differences between Type I and Type II diabetes in this context. However, before discussing the identification of incretins it is necessary to consider the question whether the hypothetical enteroinsular axis is necessary or sufficient to account for differences in glucose homeostasis observed with enteral and parenteral administration of the sugar, and whether mechanisms other than those simply dependent on portal perfusion of the liver and/or the recognized effects of insulin must be invoked.


Insulin Secretion Beta Cell Glucose Disposal Continuous Subcutaneous Insulin Infusion Gastric Inhibitory Polypeptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bayliss, W.M, Starling, E.N., The mechanism of pancreatic secretion, J. Physiol. 28: 325–353 (1902).PubMedGoogle Scholar
  2. 2.
    Moore, B., Edie, E.S., Abram, J.H., On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane, Biochem. J. 1: 28 (1906).PubMedGoogle Scholar
  3. 3.
    Laughton, N.B., Macallum, A.B., Relation of duodenal mucosa to internal secretion of pancreas, Proc. Roy. Soc. Ser. B. 111: 37–46 (1932).CrossRefGoogle Scholar
  4. 4.
    Loew, E.R., Gray, J.S., Ivy, A.C., Is duodenal hormone involved in carbohydrate metabolism? Am. J. Physiol. 129: 659–663 (1940).Google Scholar
  5. 5.
    McIntyre, N., Holdsworth, D.C., New interpretation of oral glucose tolerance, Lancet 2: 20–21 (1964).CrossRefGoogle Scholar
  6. 6.
    Dupre, J., Rojas, L., White, J.J., Unger, R.H., Beck, J.C., Effects of secretin on insulin and glucagon in portal and peripheral blood in man, Lancet 2: 26–7 (1966).PubMedCrossRefGoogle Scholar
  7. 7.
    Scow, R.O., Cornfield, J., Quantitative relations between oral and intravenous glucose tolerance curves, Am. J. Physiol. 179: 435–38 (1954).PubMedGoogle Scholar
  8. 8.
    McIntyre, N., Turner, D.S., Holdsworth, D.C., The role of the portal circulation in glucose and fructose tolerance, Diabetologia, 6: 593 (1970).PubMedCrossRefGoogle Scholar
  9. 9.
    Lickley, H.L.A., Chisholm, D.J. Rabinovitch, A., Wexler, M. Dupre, J., Effects of portacaval anastomosis on glucose tolerance in the dog: evidence of an interaction between the gut and the liver in oral glucose disposal, Metabolism 24: 1157–1168 (1975).PubMedCrossRefGoogle Scholar
  10. 10.
    Radziuk, J., Norwich, K.H., Vranic, M., Experimental validation of measurements of glucose turnover in non-steady state, Am. J. Physiol. 234: E84–E93 (1978).PubMedGoogle Scholar
  11. 11.
    Radziuk, J., McDonald, T.J., Rubenstein, D., Dupre, J., Initial splanchnic extraction of ingested glucose in normal man, Metabolism 27: 657–669 (1978b).PubMedCrossRefGoogle Scholar
  12. 12.
    Radziuk, J., Inculet, R., Effects of ingested and intravenous glucose on forearm uptake of glucose and glucogenic substrate in normal man, Diabetes 32: 977 (1983).PubMedCrossRefGoogle Scholar
  13. 13.
    Radziuk, J., The effect of additional insulin on intravenous glucose tolerance and the forearm uptake of glucose compared to that following oral glucose, Diabetologia 25: 188 (1983).Google Scholar
  14. 14.
    Dupre, J., Champion, M.C., Rodger, N.W., Replacement treatment with insulin, Clinical and Investigative Medicine 5: 109 (1982).PubMedGoogle Scholar
  15. 15.
    Unger, R.H., Ketterer, H., Dupre, J., Eisentraut, A.M., The effects of secretin, pancreozymin, and gastric on insulin and glucagon secretion in anesthetized dogs, J. Clin. Invest. 46: 630–45 (1967).PubMedCrossRefGoogle Scholar
  16. 16.
    Dupre, J., Curtis, J.D., Unger, R.H., Waddell, R.W., Beck, J.C., Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man, J. Clin. Invest. 48: 745–57 (1969).PubMedCrossRefGoogle Scholar
  17. 17.
    Brown, J.C., Dryburgh, J.R., Ross, S.A., Dupre, J., Identification and actions of gastric inhibitory polypeptide, Recent Progress in Hormone Research 31: 487–532 (1975).PubMedGoogle Scholar
  18. 18.
    Rabinovitch, A., Dupre, J., Effect of gastric-inhibitory polypeptide present in clear pancreozymin-cholecystokinin on plasma and glucagon in the rat, Endocrinology 94: 1139–1144 (1974).PubMedCrossRefGoogle Scholar
  19. 19.
    Dupre, J., Ross, A.S., Watson, D., Brown, J.C., Stimulation of insulin secretion by gastric-inhibitory polypeptide in man, J. Clin. Endocrinol. and Metab. 37: 828 (1973).CrossRefGoogle Scholar
  20. 20.
    Sarson, D.L., Wood, S.M., Kansal, P.C., Bloom, S.R., Glucose-dependent insulinotropic polypeptide augmentation of insulin, Diabetes 33: 389 (1984).PubMedCrossRefGoogle Scholar
  21. 21.
    Perley, H.J., Kipnis, D.M., Plasma insulin responses to oral and intravenous glucose on studies in normal and diabetic subjects, J. Clin. Invest. 46: 1954–1962 (1967).PubMedCrossRefGoogle Scholar
  22. 22.
    Ross, S.A., Brown, J.C., Dupre, J., Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus, Diabetes 26: 525–529 (1977).PubMedCrossRefGoogle Scholar
  23. 23.
    Crockett, S.E., Cataland, S., Falko, J., Mazzaferri, E.L., Gastric inhibitory polypeptide: responses to variable doses of glucose in normal subjects and abnormal responses to oral glucose in patients with adult onset diabetes mellitus, Diabetes 24: 413 (1975).Google Scholar
  24. 24.
    Creutzfeldt, W., Ebert, R., Wilms, B., Frerichs, H., Brown, J.C., Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels, Diabetologia 14: 15–24 (1978).PubMedCrossRefGoogle Scholar
  25. 25.
    Brown, J.C., Dryburgh, J.R., Ross, S.A., Dupre, J., Identification and actions of gastric inhibitory polypeptide, Recent Progress in Hormone Research 31: 487–532 (1975).PubMedGoogle Scholar
  26. 26.
    Verdonk, C.A., Rizza, R.A., Nelson, R.L., Go, L.L.W., Gerich, J.E., Service, F.J., Interaction of endogenous gastric- inhibitory polypeptide with pancreatic alpha and beta cell function in man, Diabetes 28: 353 (1979).Google Scholar
  27. 27.
    Stockman, F., Ebert, R., Creutzfeldt, W., Preceding hyperinsulinemia prevents demonstration of insulin effect on fat-induced gastric inhibitory polypeptide (GIP), Diabetes 33: 580 (1984).CrossRefGoogle Scholar
  28. 28.
    Dupre, J., Champion, H., Rodger, N.W., Secretion of gastric inhibitory polypeptide (GIP) in insulin-dependent (IDDH) and non-insulin-dependent (NIDDM) diabetes mellitus, Ref. Program 64th Annual Meeting of Endocrine Society, p. 342 (1982).Google Scholar
  29. 29.
    Ross, S.A., Dupre, J., Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subject, Diabetes 27: 327: 333 (1978).Google Scholar
  30. 30.
    Dupre, J., Caussignac, Y., Champion, M., Kobric, M., McDonald, T.J., Rodger, N.W., Shepherd, G.A.A., VanVliet, S., Gastrointestinal Hormones: the enteroinsular axis and the secretion of glucagon, in: “Front of Hormone Res.” W. Creutzfeldt, ed., S. Karger, Basel, publisher, Vol. 7:232–245 (1980).Google Scholar
  31. 31.
    Dupre, J., Champion, M., Rodger, N.W., Abnormal response of plasma immunoreactive glucagon to meals in insulin-dependent diabetes mellitus (IDDH) during treatment by conventional depot injection therapy (CSII), Clin and Invest. Med. (2)6: 40 (1983).Google Scholar
  32. 32.
    Felig, P., Wahren, J., Sherwin, R., Palaiologos, G., Amino acid and protein metabolism in diabetes mellitus, Arch. Intern. Med. 137: 507 (1977).PubMedCrossRefGoogle Scholar
  33. 33.
    Baer, A., Dupre, J., Prolonged intravenous infusion of gastric inhibitory polypeptide with parenteral nutrients elicits glucose intolerance and hyperinsulinemia in conscious rats, Program 63rd Annual Meeting, The Endocrine Society (1981).Google Scholar
  34. 34.
    McDonald, T.J., Jornvall, H., Nilsson, G., Vagne, M., Ghatei, M., Bloom, S.R., Mutt, V., Characterization of gastrin releasing peptide from porcine non-antral gastric tissue, Biochem. and Biophys. Res. Communications 90: 227–233 (1979).CrossRefGoogle Scholar
  35. 35.
    McDonald, T.J., Ghatei, H.A., Bloom, S.R., Track, N.S., Radziuk, J., Dupre, J., Mutt, V., A qualitative comparison of canine plasma gastroenteropancreatic hormone responses to bombesin and the procine gastrin-releasing peptide (GRP), Regulatory Peptides 2: 193–304 (1981).CrossRefGoogle Scholar
  36. 36.
    Tatmoto, K., Rokaeus, A., Jornvall, H., McDonald, T.J., Mutt, V., Galanin-a novel biologically active peptide from porcine intestine, FEBS Letters 164: 124 (1983).CrossRefGoogle Scholar
  37. 37a.
    McDonald, T.J., Tatemoto, K., Radziuk, J., Dupre, J., Galanin produces hyperglycemia in dogs, Clin. and Invest. Med. Vol. 5, No. 3 (1984).Google Scholar
  38. b. McDonald, T.J., Dupre, J., Tatemoto, K., Greenburg, J., Radziuk, J., Mutt, V., Galanin inhibits insulin secretion and induces hyperglycemia in dogs, Manuscript submitted to Diabetes.Google Scholar
  39. 38.
    Altzuler, N., Gottlieb, B., Hampshire, J., Interaction of somatostatin, glucagon and insulin on hepatic glucose output in the normal dog, Diabetes 25: 116 (1976).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • J. Dupre
    • 1
  • A. Baer
    • 1
  • M. Lee
    • 1
  • T. J. McDonald
    • 1
  • J. Radziuk
    • 1
  • N. W. Rodger
    • 1
  • S. Sullivan
    • 1
  1. 1.Department of MedicineUniversity of Western OntarioLondonCanada

Personalised recommendations